What does the Landscape Review cover?
- Drug Landscape: An overview of top modalities, new assets and bispecific targets in H1 2024, plus a spotlight on cytokine-armored cell therapies.
- Trial Landscape: Insights into trial initiation trends, autoimmune disease modalities, and combinations trials.
- The Commercial Landscape: Analysis of deal values, development phases, company locations, and funding rounds.
- Regulatory Announcements: Key regulatory milestones and IND/CTA approvals from H1 2024.
- The Future of Cytokines: Predictions on target selection and future trends in the cytokine field, as well as a look at trials ending this year.
You may also be interested in...
H1 2024 Cytokine Landscape Review
H1 2024 Immune Tolerance Landscape Review
H1 2024 Bispecific Landscape Review
H1 2024 Checkpoint Landscape Review
H1 2024 ADC Landscape Review
Investment Trends in Early-Stage Biopharma: A Beacon Data Perspective
Find out more
Beacon is the essential decision-support tool for developers of complex therapeutics. Our market-defining, proprietary ontologies combined with the most accurate and comprehensive life sciences data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
Each dataset features proprietary, hyper-relevant search and filtering tailored to specific modalities, in-depth data, plus additional market insight curated by our subject matter experts. Beacon is here to support you in making these decisions with confidence through our encompassing database solution.
With Beacon, you can make drug development decisions with confidence. This is why 23 out of the world’s top 25 drug developers trust us.
Any questions? Get in touch
Our dedicated account and research teams can help you with questions by showing you how this insight and data is collated on Beacon.
